

# David A Isenberg

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/2161950/david-a-isenberg-publications-by-citations.pdf>

**Version:** 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

512  
papers

33,052  
citations

83  
h-index

170  
g-index

597  
ext. papers

38,488  
ext. citations

5.8  
avg. IF

7.13  
L-index

#	Paper	IF	Citations
512	Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , <b>2012</b> , 64, 2677-86		2688
511	The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , <b>1996</b> , 39, 363-9		1688
510	Systemic lupus erythematosus. <i>New England Journal of Medicine</i> , <b>2008</b> , 358, 929-39	59.2	1367
509	Preliminary criteria for the classification of Sjögren's syndrome. Results of a prospective concerted action supported by the European Community. <i>Arthritis and Rheumatism</i> , <b>1993</b> , 36, 340-7		1275
508	CD19(+)CD24(hi)CD38(hi) B cells exhibit regulatory capacity in healthy individuals but are functionally impaired in systemic Lupus Erythematosus patients. <i>Immunity</i> , <b>2010</b> , 32, 129-40	32.3	1140
507	Compromised function of regulatory T cells in rheumatoid arthritis and reversal by anti-TNFalpha therapy. <i>Journal of Experimental Medicine</i> , <b>2004</b> , 200, 277-85	16.6	991
506	Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. <i>Arthritis and Rheumatism</i> , <b>2010</b> , 62, 222-33		866
505	Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. <i>Journal of the American Society of Nephrology: JASN</i> , <b>2009</b> , 20, 1103-12	12.7	718
504	Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. <i>Annals of the Rheumatic Diseases</i> , <b>2012</b> , 71, 1771-82	2.4	692
503	The reliability of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index in patients with systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , <b>1997</b> , 40, 809-13		505
502	An open study of B lymphocyte depletion in systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , <b>2002</b> , 46, 2673-7		469
501	CD19+CD24hiCD38hi B cells maintain regulatory T cells while limiting TH1 and TH17 differentiation. <i>Science Translational Medicine</i> , <b>2013</b> , 5, 173ra23	17.5	449
500	Systemic lupus erythematosus. <i>Lancet, The</i> , <b>2014</b> , 384, 1878-1888	40	439
499	Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis. <i>New England Journal of Medicine</i> , <b>2011</b> , 365, 1886-95	59.2	413
498	Malignant lymphoma in primary Sjögren's syndrome: a multicenter, retrospective, clinical study by the European Concerted Action on Sjögren's Syndrome. <i>Arthritis and Rheumatism</i> , <b>1999</b> , 42, 1765-72		404
497	Treat-to-target in systemic lupus erythematosus: recommendations from an international task force. <i>Annals of the Rheumatic Diseases</i> , <b>2014</b> , 73, 958-67	2.4	388
496	BILAG 2004. Development and initial validation of an updated version of the British Isles Lupus Assessment Group's disease activity index for patients with systemic lupus erythematosus. <i>Rheumatology</i> , <b>2005</b> , 44, 902-6	3.9	363

495	Factors associated with damage accrual in patients with systemic lupus erythematosus: results from the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort. <i>Annals of the Rheumatic Diseases</i> , <b>2015</b> , 74, 1706-13	2.4	250
494	International consensus outcome measures for patients with idiopathic inflammatory myopathies. Development and initial validation of myositis activity and damage indices in patients with adult onset disease. <i>Rheumatology</i> , <b>2004</b> , 43, 49-54	3.9	249
493	Selective targeting of B cells with agonistic anti-CD40 is an efficacious strategy for the generation of induced regulatory T2-like B cells and for the suppression of lupus in MRL/lpr mice. <i>Journal of Immunology</i> , <b>2009</b> , 182, 3492-3502	5.3	236
492	Rivaroxaban versus warfarin to treat patients with thrombotic antiphospholipid syndrome, with or without systemic lupus erythematosus (RAPS): a randomised, controlled, open-label, phase 2/3, non-inferiority trial. <i>Lancet Haematology</i> , <b>2016</b> , 3, e426-36	14.6	231
491	Influence of race/ethnicity on response to lupus nephritis treatment: the ALMS study. <i>Rheumatology</i> , <b>2010</b> , 49, 128-40	3.9	224
490	Polymorphism at the C-reactive protein locus influences gene expression and predisposes to systemic lupus erythematosus. <i>Human Molecular Genetics</i> , <b>2004</b> , 13, 137-47	5.6	223
489	The frequency and outcome of lupus nephritis: results from an international inception cohort study. <i>Rheumatology</i> , <b>2016</b> , 55, 252-62	3.9	210
488	Current evidence for the induction of autoimmune rheumatic manifestations by cytokine therapy. <i>Arthritis and Rheumatism</i> , <b>2000</b> , 43, 1431-42		206
487	A Regulatory Feedback between Plasmacytoid Dendritic Cells and Regulatory B Cells Is Aberrant in Systemic Lupus Erythematosus. <i>Immunity</i> , <b>2016</b> , 44, 683-697	32.3	205
486	A retrospective seven-year analysis of the use of B cell depletion therapy in systemic lupus erythematosus at University College London Hospital: the first fifty patients. <i>Arthritis and Rheumatism</i> , <b>2009</b> , 61, 482-7		204
485	Measures of adult and juvenile dermatomyositis, polymyositis, and inclusion body myositis: Physician and Patient/Parent Global Activity, Manual Muscle Testing (MMT), Health Assessment Questionnaire (HAQ)/Childhood Health Assessment Questionnaire (C-HAQ), Childhood Myositis Assessment Scale (CMAS), Myositis Disease Activity Assessment Tool (MDAAT), Disease Activity	4.7	203
484	Cancer risk in systemic lupus: an updated international multi-centre cohort study. <i>Journal of Autoimmunity</i> , <b>2013</b> , 42, 130-5	15.5	194
483	Quantitative Muscle T. <i>Arthritis Care and Research</i> , <b>2011</b> , 63 Suppl 11, S118-37		
483	A comparative analysis of disease-associated changes in the galactosylation of serum IgG. <i>Journal of Autoimmunity</i> , <b>1989</b> , 2, 101-14	15.5	193
482	Efficacy and safety of ataccept for prevention of flares in patients with moderate-to-severe systemic lupus erythematosus (SLE): 52-week data (APRIL-SLE randomised trial). <i>Annals of the Rheumatic Diseases</i> , <b>2015</b> , 74, 2006-15	2.4	189
481	Fifty years of anti-ds DNA antibodies: are we approaching journey's end?. <i>Rheumatology</i> , <b>2007</b> , 46, 1052-69	6.9	188
480	Development and validation of a disease-specific health-related quality of life measure, the LupusQoL, for adults with systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , <b>2007</b> , 57, 972-9		185
479	Efficacy of rituximab in 164 patients with biopsy-proven lupus nephritis: pooled data from European cohorts. <i>Autoimmunity Reviews</i> , <b>2012</b> , 11, 357-64	13.6	176
478	A framework for remission in SLE: consensus findings from a large international task force on definitions of remission in SLE (DORIS). <i>Annals of the Rheumatic Diseases</i> , <b>2017</b> , 76, 554-561	2.4	175

477	Increased circulating platelet-leucocyte complexes and platelet activation in patients with antiphospholipid syndrome, systemic lupus erythematosus and rheumatoid arthritis. <i>British Journal of Haematology</i> , <b>2001</b> , 115, 451-9	4.5	173
476	The mosaic of autoimmunity. <i>Trends in Immunology</i> , <b>1989</b> , 10, 123-6		164
475	Human IgG anti-DNA antibodies deposit in kidneys and induce proteinuria in SCID mice. <i>Kidney International</i> , <b>1995</b> , 48, 705-11	9.9	163
474	Damage and mortality in a group of British patients with systemic lupus erythematosus followed up for over 10 years. <i>Rheumatology</i> , <b>2009</b> , 48, 673-5	3.9	160
473	Binding of cytoskeletal proteins by monoclonal anti-DNA lupus autoantibodies. <i>Clinical Immunology and Immunopathology</i> , <b>1984</b> , 31, 261-71		156
472	The British Society for Rheumatology guideline for the management of systemic lupus erythematosus in adults. <i>Rheumatology</i> , <b>2018</b> , 57, e1-e45	3.9	150
471	EULAR Sjögren's syndrome disease activity index (ESSDAI): a user guide. <i>RMD Open</i> , <b>2015</b> , 1, e000022	5.9	150
470	Lipid-antigen presentation by CD1d(+) B cells is essential for the maintenance of invariant natural killer T cells. <i>Immunity</i> , <b>2012</b> , 36, 477-90	32.3	150
469	Altered lipid raft-associated signaling and ganglioside expression in T lymphocytes from patients with systemic lupus erythematosus. <i>Journal of Clinical Investigation</i> , <b>2004</b> , 113, 1176-1187	15.9	144
468	Measures of adult systemic lupus erythematosus: updated version of British Isles Lupus Assessment Group (BILAG 2004), European Consensus Lupus Activity Measurements (ECLAM), Systemic Lupus Activity Measure, Revised (SLAM-R), Systemic Lupus Activity Questionnaire for Population Studies (SLAQ), Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K),	4.7	132
467	B cell depletion therapy in systemic lupus erythematosus: long-term follow-up and predictors of response. <i>Annals of the Rheumatic Diseases</i> , <b>2007</b> , 66, 1259-62	2.4	122
466	The use of Systemic Lupus Erythematosus Disease Activity Index-2000 to define active disease and minimal clinically meaningful change based on data from a large cohort of systemic lupus erythematosus patients. <i>Rheumatology</i> , <b>2011</b> , 50, 982-8	3.9	120
465	Antiribosomal P protein antibodies in systemic lupus erythematosus. A reappraisal. <i>Arthritis and Rheumatism</i> , <b>1994</b> , 37, 307-15		120
464	Pregnancy outcome in adult-onset idiopathic inflammatory myopathy. <i>British Journal of Rheumatology</i> , <b>2003</b> , 42, 1168-72		118
463	Mycobacteria and autoimmunity. <i>Trends in Immunology</i> , <b>1988</b> , 9, 178-82		118
462	Seizure disorders in systemic lupus erythematosus results from an international, prospective, inception cohort study. <i>Annals of the Rheumatic Diseases</i> , <b>2012</b> , 71, 1502-9	2.4	115
461	Binding of antiphospholipid antibodies to discontinuous epitopes on domain I of human beta(2)-glycoprotein I: mutation studies including residues R39 to R43. <i>Arthritis and Rheumatism</i> , <b>2007</b> , 56, 280-90		115
460	Efficacy and Safety of Atacicept in Patients With Systemic Lupus Erythematosus: Results of a Twenty-Four-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Arm, Phase IIb Study. <i>Arthritis and Rheumatology</i> , <b>2018</b> , 70, 266-276	9.5	114

459	Th17 cells are restrained by Treg cells via the inhibition of interleukin-6 in patients with rheumatoid arthritis responding to anti-tumor necrosis factor antibody therapy. <i>Arthritis and Rheumatism</i> , <b>2012</b> , 64, 3129-38		112
458	Signal transducer and activator of transcription-1 and heat shock factor-1 interact and activate the transcription of the Hsp-70 and Hsp-90beta gene promoters. <i>Journal of Biological Chemistry</i> , <b>1999</b> , 274, 1723-8	5.4	109
457	Defining Clinical Improvement in Adult and Juvenile Myositis. <i>Journal of Rheumatology</i> , <b>2003</b> , 30, 603-174.1		108
456	Nonrenal disease activity following mycophenolate mofetil or intravenous cyclophosphamide as induction treatment for lupus nephritis: findings in a multicenter, prospective, randomized, open-label, parallel-group clinical trial. <i>Arthritis and Rheumatism</i> , <b>2010</b> , 62, 211-21		106
455	Atorvastatin restores Lck expression and lipid raft-associated signaling in T cells from patients with systemic lupus erythematosus. <i>Journal of Immunology</i> , <b>2006</b> , 177, 7416-22	5.3	106
454	Multiple serologic reactions and their relationship to clinical activity in systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , <b>1984</b> , 27, 132-8		106
453	Predictors of lymphoma development in primary Sjögren's syndrome. <i>Seminars in Arthritis and Rheumatism</i> , <b>1998</b> , 28, 80-7	5.3	105
452	Impaired recognition of apoptotic neutrophils by the C1q/calreticulin and CD91 pathway in systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , <b>2006</b> , 54, 1543-56		104
451	Lupus disease activity and the risk of subsequent organ damage and mortality in a large lupus cohort. <i>Rheumatology</i> , <b>2012</b> , 51, 491-8	3.9	100
450	Assessment of a lupus nephritis cohort over a 30-year period. <i>Rheumatology</i> , <b>2011</b> , 50, 1424-30	3.9	99
449	Utilization of the VH4-21 gene segment by anti-DNA antibodies from patients with systemic lupus erythematosus. <i>Journal of Autoimmunity</i> , <b>1993</b> , 6, 809-25	15.5	99
448	Normalizing glycosphingolipids restores function in CD4+ T cells from lupus patients. <i>Journal of Clinical Investigation</i> , <b>2014</b> , 124, 712-24	15.9	99
447	Efficacy and safety of epratuzumab in patients with moderate/severe flaring systemic lupus erythematosus: results from two randomized, double-blind, placebo-controlled, multicentre studies (ALLEVIATE) and follow-up. <i>Rheumatology</i> , <b>2013</b> , 52, 1313-22	3.9	98
446	Decreased Lyn expression and translocation to lipid raft signaling domains in B lymphocytes from patients with systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , <b>2005</b> , 52, 3955-65		96
445	IgG anti-endothelial cell autoantibodies from patients with systemic lupus erythematosus or systemic vasculitis stimulate the release of two endothelial cell-derived mediators, which enhance adhesion molecule expression and leukocyte adhesion in an autocrine manner. <i>Arthritis and Rheumatism</i> , <b>1999</b> , 42, 631-40		96
444	Effect of gender on clinical presentation in systemic lupus erythematosus. <i>Rheumatology</i> , <b>2013</b> , 52, 2108-15	3.5	95
443	B-cell depletion in SLE: clinical and trial experience with rituximab and ocrelizumab and implications for study design. <i>Arthritis Research and Therapy</i> , <b>2013</b> , 15 Suppl 1, S2	5.7	94
442	Genome-wide association study of dermatomyositis reveals genetic overlap with other autoimmune disorders. <i>Arthritis and Rheumatism</i> , <b>2013</b> , 65, 3239-47		94

441	Inhibition of caspase-3-mediated poly(ADP-ribose) polymerase (PARP) apoptotic cleavage by human PARP autoantibodies and effect on cells undergoing apoptosis. <i>Journal of Biological Chemistry</i> , <b>2000</b> , 275, 9043-6	5.4	91
440	The role of IgG glycoforms in the pathogenesis of rheumatoid arthritis. <i>Seminars in Immunopathology</i> , <b>1988</b> , 10, 231-49		91
439	Elevated serum BAFF levels are associated with rising anti-double-stranded DNA antibody levels and disease flare following B cell depletion therapy in systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , <b>2013</b> , 65, 2672-9		90
438	In adult onset myositis, the presence of interstitial lung disease and myositis specific/associated antibodies are governed by HLA class II haplotype, rather than by myositis subtype. <i>Arthritis Research and Therapy</i> , <b>2006</b> , 8, R13	5.7	90
437	The origin, sequence, structure, and consequences of developing anti-DNA antibodies. A human perspective. <i>Arthritis and Rheumatism</i> , <b>1994</b> , 37, 169-80		89
436	AIDS virus infection and autoimmunity: a perspective of the clinical, immunological, and molecular origins of the autoallergic pathologies associated with HIV disease. <i>Clinical Immunology and Immunopathology</i> , <b>1991</b> , 58, 163-80		89
435	Relationship between anti-dsDNA, anti-nucleosome and anti-alpha-actinin antibodies and markers of renal disease in patients with lupus nephritis: a prospective longitudinal study. <i>Arthritis Research and Therapy</i> , <b>2009</b> , 11, R154	5.7	88
434	Antibodies to apolipoprotein A-I, high-density lipoprotein, and C-reactive protein are associated with disease activity in patients with systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , <b>2010</b> , 62, 845-54		88
433	The 52 000 MW Ro/SS-A autoantigen in Sjögren's syndrome/systemic lupus erythematosus (Ro52) is an interferon-gamma inducible tripartite motif protein associated with membrane proximal structures. <i>Immunology</i> , <b>2002</b> , 106, 246-56	7.8	88
432	Respiratory manifestations of systemic lupus erythematosus: old and new concepts. <i>Best Practice and Research in Clinical Rheumatology</i> , <b>2009</b> , 23, 469-80	5.3	86
431	Numerical scoring for the BILAG-2004 index. <i>Rheumatology</i> , <b>2010</b> , 49, 1665-9	3.9	84
430	Lymphoma risk in systemic lupus: effects of disease activity versus treatment. <i>Annals of the Rheumatic Diseases</i> , <b>2014</b> , 73, 138-42	2.4	83
429	Systemic lupus erythematosus and other autoimmune rheumatic diseases: challenges to treatment. <i>Lancet, The</i> , <b>2013</b> , 382, 809-18	4.0	83
428	Urinary neutrophil gelatinase-associated lipocalin as a novel biomarker for disease activity in lupus nephritis. <i>Rheumatology</i> , <b>2010</b> , 49, 960-71	3.9	82
427	Prevalence of conventional and lupus-specific risk factors for cardiovascular disease in patients with systemic lupus erythematosus: A case-control study. <i>Arthritis and Rheumatism</i> , <b>2006</b> , 55, 892-9		81
426	Overrepresentation of the Fc gamma receptor type IIA R131/R131 genotype in caucasoid systemic lupus erythematosus patients with autoantibodies to C1q and glomerulonephritis. <i>Arthritis and Rheumatism</i> , <b>1999</b> , 42, 1828-32		81
425	Obinutuzumab induces superior B-cell cytotoxicity to rituximab in rheumatoid arthritis and systemic lupus erythematosus patient samples. <i>Rheumatology</i> , <b>2017</b> , 56, 1227-1237	3.9	78
424	A retrospective study of long-term outcomes in 152 patients with primary Sjögren's syndrome: 25-year experience. <i>Clinical Medicine</i> , <b>2014</b> , 14, 322-322	1.9	78

4 <sup>23</sup>	Association of antinucleosome antibodies with disease flare in serologically active clinically quiescent patients with systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , <b>2006</b> , 55, 900-4		78
4 <sup>22</sup>	Is alpha-actinin a target for pathogenic anti-DNA antibodies in lupus nephritis?. <i>Arthritis and Rheumatism</i> , <b>2004</b> , 50, 866-70		78
4 <sup>21</sup>	New therapies for systemic lupus erythematosus - past imperfect, future tense. <i>Nature Reviews Rheumatology</i> , <b>2019</b> , 15, 403-412	8.1	77
4 <sup>20</sup>	Mood Disorders in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study. <i>Arthritis and Rheumatology</i> , <b>2015</b> , 67, 1837-47	9.5	77
4 <sup>19</sup>	Revised British Isles Lupus Assessment Group 2004 index: a reliable tool for assessment of systemic lupus erythematosus activity. <i>Arthritis and Rheumatism</i> , <b>2006</b> , 54, 3300-5		77
4 <sup>18</sup>	Genetic, structural and functional properties of an IgG DNA-binding monoclonal antibody from a lupus patient with nephritis. <i>European Journal of Immunology</i> , <b>1998</b> , 28, 339-50	6.1	76
4 <sup>17</sup>	British Isles Lupus Assessment Group 2004 index is valid for assessment of disease activity in systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , <b>2007</b> , 56, 4113-9		76
4 <sup>16</sup>	The association of anti-Ro52 autoantibodies with myositis and scleroderma autoantibodies. <i>Journal of Autoimmunity</i> , <b>1999</b> , 12, 137-42	15.5	76
4 <sup>15</sup>	The BILAG-2004 index is sensitive to change for assessment of SLE disease activity. <i>Rheumatology</i> , <b>2009</b> , 48, 691-5	3.9	74
4 <sup>14</sup>	Increased ubiquitination and reduced expression of LCK in T lymphocytes from patients with systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , <b>2003</b> , 48, 1343-54		74
4 <sup>13</sup>	Influence of geolocation and ethnicity on the phenotypic expression of primary Sjögren's syndrome at diagnosis in 8310 patients: a cross-sectional study from the Big Data Sjögren Project Consortium. <i>Annals of the Rheumatic Diseases</i> , <b>2017</b> , 76, 1042-1050	2.4	73
4 <sup>12</sup>	Anti B cell therapy (rituximab) in the treatment of autoimmune diseases. <i>Current Opinion in Pharmacology</i> , <b>2004</b> , 4, 398-402	5.1	72
4 <sup>11</sup>	Altered lipid raft-associated signaling and ganglioside expression in T lymphocytes from patients with systemic lupus erythematosus. <i>Journal of Clinical Investigation</i> , <b>2004</b> , 113, 1176-87	15.9	71
4 <sup>10</sup>	The rate and pattern of organ damage in late onset systemic lupus erythematosus. <i>Journal of Rheumatology</i> , <b>2002</b> , 29, 913-7	4.1	71
4 <sup>09</sup>	Prevalence, patterns of disease and outcome in patients with systemic lupus erythematosus who develop severe haematological problems. <i>British Journal of Rheumatology</i> , <b>2003</b> , 42, 230-4		69
4 <sup>08</sup>	An assessment of disease flare in patients with systemic lupus erythematosus: a comparison of BILAG 2004 and the flare version of SELENA. <i>Annals of the Rheumatic Diseases</i> , <b>2011</b> , 70, 54-9	2.4	68
4 <sup>07</sup>	Agalactosyl IgG: an aid to differential diagnosis in early synovitis. <i>Arthritis and Rheumatism</i> , <b>1991</b> , 34, 1425-9		68
4 <sup>06</sup>	Rituximab in the treatment of inflammatory myopathies: a review. <i>Rheumatology</i> , <b>2017</b> , 56, 26-36	3.9	67

405	The efficacy of repeated treatment with B-cell depletion therapy in systemic lupus erythematosus: an evaluation. <i>Rheumatology</i> , <b>2011</b> , 50, 1401-8	3.9	67
404	Splenic involvement in rheumatic diseases. <i>Seminars in Arthritis and Rheumatism</i> , <b>1997</b> , 27, 141-55	5.3	67
403	2016 American College of Rheumatology/European League Against Rheumatism criteria for minimal, moderate, and major clinical response in adult dermatomyositis and polymyositis: An International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology International Trials Organisation Collaborative Initiative. <i>Annals of the Rheumatic Diseases</i> , <b>2017</b> ,	2.4	65
402	Headache in systemic lupus erythematosus: results from a prospective, international inception cohort study. <i>Arthritis and Rheumatism</i> , <b>2013</b> , 65, 2887-97		65
401	Clinical associations of the metabolic syndrome in systemic lupus erythematosus: data from an international inception cohort. <i>Annals of the Rheumatic Diseases</i> , <b>2013</b> , 72, 1308-14	2.4	65
400	Risk factors for clinical coronary heart disease in systemic lupus erythematosus: the lupus and atherosclerosis evaluation of risk (LASER) study. <i>Journal of Rheumatology</i> , <b>2010</b> , 37, 322-9	4.1	65
399	Health-related utility values of patients with primary Sjögren's syndrome and its predictors. <i>Annals of the Rheumatic Diseases</i> , <b>2014</b> , 73, 1362-8	2.4	63
398	The BILAG multi-centre open randomized controlled trial comparing ciclosporin vs azathioprine in patients with severe SLE. <i>Rheumatology</i> , <b>2010</b> , 49, 723-32	3.9	63
397	Syndromes and complications of interferon therapy. <i>Current Opinion in Rheumatology</i> , <b>2007</b> , 19, 61-6	5.3	62
396	Childhood- and adult-onset lupus: an update of similarities and differences. <i>Expert Review of Clinical Immunology</i> , <b>2009</b> , 5, 391-403	5.1	61
395	Functional and modelling studies of the binding of human monoclonal anti-DNA antibodies to DNA. <i>Molecular Immunology</i> , <b>1996</b> , 33, 471-83	4.3	60
394	The substantial burden of systemic lupus erythematosus on the productivity and careers of patients: a European patient-driven online survey. <i>Rheumatology</i> , <b>2013</b> , 52, 2292-301	3.9	58
393	Effects of polyclonal IgG derived from patients with different clinical types of the antiphospholipid syndrome on monocyte signaling pathways. <i>Journal of Immunology</i> , <b>2010</b> , 184, 6622-8	5.3	58
392	Early treatment with rituximab in newly diagnosed systemic lupus erythematosus patients: a steroid-sparing regimen. <i>Rheumatology</i> , <b>2012</b> , 51, 476-81	3.9	58
391	Reliability and validity of the myositis disease activity assessment tool. <i>Arthritis and Rheumatism</i> , <b>2008</b> , 58, 3593-9		58
390	Susceptibility of patients with rheumatic diseases to B-cell non-Hodgkin lymphoma. <i>Nature Reviews Rheumatology</i> , <b>2011</b> , 7, 360-8	8.1	54
389	Current status on B-cell depletion therapy in autoimmune diseases other than rheumatoid arthritis. <i>Autoimmunity Reviews</i> , <b>2009</b> , 9, 82-9	13.6	54
388	The use of alternative medical therapies in patients with systemic lupus erythematosus. Trination Study Group. <i>Arthritis and Rheumatism</i> , <b>2000</b> , 43, 1410-8		54



387	The diagnosis and management of the haematologic manifestations of lupus. <i>Journal of Autoimmunity</i> , <b>2016</b> , 74, 139-160	15.5	53
386	B-cell-depletion therapy in SLE--what are the current prospects for its acceptance?. <i>Nature Reviews Rheumatology</i> , <b>2009</b> , 5, 711-6	8.1	53
385	Surface expression of heat shock protein 90 by blood mononuclear cells from patients with systemic lupus erythematosus. <i>Journal of Autoimmunity</i> , <b>1992</b> , 5, 803-14	15.5	52
384	Impact of early disease factors on metabolic syndrome in systemic lupus erythematosus: data from an international inception cohort. <i>Annals of the Rheumatic Diseases</i> , <b>2015</b> , 74, 1530-6	2.4	51
383	Global trends, potential mechanisms and early detection of organ damage in SLE. <i>Nature Reviews Rheumatology</i> , <b>2013</b> , 9, 301-10	8.1	51
382	The systemic lupus erythematosus Tri-Nation study: cumulative indirect costs. <i>Arthritis and Rheumatism</i> , <b>2007</b> , 57, 64-70		51
381	Diagnostic criteria for polymyositis and dermatomyositis. <i>Lancet, The</i> , <b>2003</b> , 362, 1762-3; author reply 1763	4.0	51
380	TRIM21 and the Function of Antibodies inside Cells. <i>Trends in Immunology</i> , <b>2017</b> , 38, 916-926	14.4	50
379	How do antiphospholipid antibodies bind beta2-glycoprotein I?. <i>Arthritis and Rheumatism</i> , <b>2003</b> , 48, 2111-21		50
378	Analysis of B-cell epitopes of the Ro/SS-A autoantigen. <i>Trends in Immunology</i> , <b>1999</b> , 20, 234-40		50
377	Measuring IgA Anti- $\beta$ -Glycoprotein I and IgG/IgA Anti-Domain I Antibodies Adds Value to Current Serological Assays for the Antiphospholipid Syndrome. <i>PLoS ONE</i> , <b>2016</b> , 11, e0156407	3.7	50
376	Proof-of-concept study demonstrating the pathogenicity of affinity-purified IgG antibodies directed to domain I of $\beta$ -glycoprotein I in a mouse model of anti-phospholipid antibody-induced thrombosis. <i>Rheumatology</i> , <b>2015</b> , 54, 722-7	3.9	49
375	B-cell numbers and phenotype at clinical relapse following rituximab therapy differ in SLE patients according to anti-dsDNA antibody levels. <i>Rheumatology</i> , <b>2012</b> , 51, 1208-15	3.9	49
374	Human immunodeficiency virus infection in systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , <b>1997</b> , 40, 1168-72		49
373	Systemic lupus international collaborating clinics renal activity/response exercise: development of a renal activity score and renal response index. <i>Arthritis and Rheumatism</i> , <b>2008</b> , 58, 1784-8		49
372	Short-term efficacy and safety of rituximab therapy in refractory systemic lupus erythematosus: results from the British Isles Lupus Assessment Group Biologics Register. <i>Rheumatology</i> , <b>2018</b> , 57, 470-479	3.9	47
371	Endorsement and memory bias of self-referential pain stimuli in depressed pain patients. <i>British Journal of Clinical Psychology</i> , <b>1995</b> , 34, 267-77	3.6	47
370	The role of the human anti-DNA idiotype 16/6 in autoimmunity. <i>Clinical Immunology and Immunopathology</i> , <b>1989</b> , 51, 313-25		47

369	Comparison of DNA antibody idiotypes in human sera: an international collaborative study of 19 idiotypes from 11 different laboratories. <i>Journal of Autoimmunity</i> , <b>1990</b> , 3, 393-414	15.5	47
368	Examining the prevalence of non-criteria anti-phospholipid antibodies in patients with anti-phospholipid syndrome: a systematic review. <i>Rheumatology</i> , <b>2015</b> , 54, 2042-50	3.9	46
367	Antinuclear Antibody-Negative Systemic Lupus Erythematosus in an International Inception Cohort. <i>Arthritis Care and Research</i> , <b>2019</b> , 71, 893-902	4.7	46
366	Clinical improvements in proliferative vs membranous lupus nephritis following B-cell depletion: pooled data from two cohorts. <i>Rheumatology</i> , <b>2010</b> , 49, 1502-4	3.9	46
365	Autonomic symptoms are common and are associated with overall symptom burden and disease activity in primary Sjogren's syndrome. <i>Annals of the Rheumatic Diseases</i> , <b>2012</b> , 71, 1973-9	2.4	46
364	Preferential secretion of a common anti-DNA idotype (16/6 Id) and anti-polynucleotide antibodies by normal mononuclear cells following stimulation with <i>Klebsiella pneumoniae</i> . <i>Immunology Letters</i> , <b>1986</b> , 12, 313-9	4.1	46
363	Exploring BAFF: its expression, receptors and contribution to the immunopathogenesis of Sjogren's syndrome. <i>Rheumatology</i> , <b>2016</b> , 55, 1548-55	3.9	45
362	A retrospective study of long-term outcomes in 152 patients with primary Sjogren's syndrome: 25-year experience. <i>Clinical Medicine</i> , <b>2014</b> , 14, 157-64	1.9	44
361	The LupusQoL and associations with demographics and clinical measurements in patients with systemic lupus erythematosus. <i>Journal of Rheumatology</i> , <b>2010</b> , 37, 2273-9	4.1	44
360	Abnormal CTLA-4 function in T cells from patients with systemic lupus erythematosus. <i>European Journal of Immunology</i> , <b>2010</b> , 40, 569-78	6.1	44
359	Internalization of rituximab and the efficiency of B Cell depletion in rheumatoid arthritis and systemic lupus erythematosus. <i>Arthritis and Rheumatology</i> , <b>2015</b> , 67, 2046-55	9.5	43
358	25-hydroxyvitamin D and cardiovascular disease in patients with systemic lupus erythematosus: data from a large international inception cohort. <i>Arthritis Care and Research</i> , <b>2014</b> , 66, 1167-76	4.7	43
357	Natural killer T cells in families of patients with systemic lupus erythematosus: their possible role in regulation of IGG production. <i>Arthritis and Rheumatism</i> , <b>2007</b> , 56, 303-10		43
356	Biologic treatment in Sjogren's syndrome. <i>Rheumatology</i> , <b>2015</b> , 54, 219-30	3.9	42
355	Analysis of Complete Remission in Systemic Lupus Erythematosus Patients Over a 32-Year Period. <i>Arthritis Care and Research</i> , <b>2016</b> , 68, 981-7	4.7	42
354	Poor response of anti-SRP-positive idiopathic immune myositis to B-cell depletion. <i>Rheumatology</i> , <b>2009</b> , 48, 594-5	3.9	41
353	Serial studies of the IgG subclass and functional affinity of DNA antibodies in systemic lupus erythematosus. <i>Journal of Autoimmunity</i> , <b>1988</b> , 1, 483-94	15.5	41
352	B-cell depletion with rituximab in the COVID-19 pandemic: where do we stand?. <i>Lancet Rheumatology</i> , <b>2020</b> , 2, e589-e590	14.2	41

351	B cell depletion in autoimmune disease. <i>Arthritis Research</i> , <b>2003</b> , 5 Suppl 4, S17-21		40
350	Safety and efficacy of hCDR1 (Edratide) in patients with active systemic lupus erythematosus: results of phase II study. <i>Lupus Science and Medicine</i> , <b>2015</b> , 2, e000104	4.6	39
349	DNA-damaging autoantibodies and cancer: the lupus butterfly theory. <i>Nature Reviews Rheumatology</i> , <b>2016</b> , 12, 429-34	8.1	39
348	Rituximab as early therapy for pulmonary haemorrhage in systemic lupus erythematosus. <i>Rheumatology</i> , <b>2010</b> , 49, 392-4	3.9	39
347	52-kDa Ro/SSA epitopes preferentially recognized by antibodies from mothers of children with neonatal lupus and congenital heart block. <i>Arthritis Research and Therapy</i> , <b>2006</b> , 8, R4	5.7	39
346	Autoimmune thrombocytopenia in primary antiphospholipid syndrome and systemic lupus erythematosus: the response to splenectomy. <i>Seminars in Arthritis and Rheumatism</i> , <b>1998</b> , 28, 20-5	5.3	38
345	2016 American College of Rheumatology/European League Against Rheumatism Criteria for Minimal, Moderate, and Major Clinical Response in Juvenile Dermatomyositis: An International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology International Trials Organisation Collaborative Initiative. <i>Arthritis and Rheumatology</i> , <b>2017</b> , 69, 911-923	9.5	36
344	Cerebrovascular Events in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study. <i>Arthritis Care and Research</i> , <b>2018</b> , 70, 1478-1487	4.7	36
343	CD5 expression promotes IL-10 production through activation of the MAPK/Erk pathway and upregulation of TRPC1 channels in B lymphocytes. <i>Cellular and Molecular Immunology</i> , <b>2018</b> , 15, 158-170 <sup>15.4</sup>		36
342	A comparison of the outcome of adolescent and adult-onset systemic lupus erythematosus. <i>Rheumatology</i> , <b>2014</b> , 53, 1130-5	3.9	36
341	Pragmatic Treatment of Patients With Systemic Lupus Erythematosus With Rituximab: Long-Term Effects on Serum Immunoglobulins. <i>Arthritis Care and Research</i> , <b>2017</b> , 69, 857-866	4.7	36
340	Altered lipid raft-associated proximal signaling and translocation of CD45 tyrosine phosphatase in B lymphocytes from patients with systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , <b>2007</b> , 56, 291-302		36
339	Pulmonary hypertension in autoimmune rheumatic diseases: where are we now?. <i>Arthritis and Rheumatism</i> , <b>2002</b> , 46, 1997-2009		36
338	Serial analysis of Ro/SSA and La/SSB antibody levels and correlation with clinical disease activity in patients with systemic lupus erythematosus. <i>Scandinavian Journal of Rheumatology</i> , <b>2002</b> , 31, 133-139	1.9	35
337	CD19CD24CD38 B Cells Are Expanded in Juvenile Dermatomyositis and Exhibit a Pro-Inflammatory Phenotype After Activation Through Toll-Like Receptor 7 and Interferon- $\beta$ . <i>Frontiers in Immunology</i> , <b>2018</b> , 9, 1372	8.4	34
336	Estimating indirect costs in primary Sjögren's syndrome. <i>Journal of Rheumatology</i> , <b>2010</b> , 37, 1010-5	4.1	34
335	Protein phosphorylation and kinome profiling reveal altered regulation of multiple signaling pathways in B lymphocytes from patients with systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , <b>2010</b> , 62, 2412-23		34
334	Single nucleotide polymorphic haplotypes of the interleukin-10 5' flanking region are not associated with renal disease or serology in Caucasian patients with systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , <b>1999</b> , 42, 2017-8		34

333	DNA antibody idiotypes: a review of their genetic, clinical, and immunopathologic features. <i>Seminars in Arthritis and Rheumatism</i> , <b>1987</b> , 16, 245-52	5.3	34
332	Off-label use of rituximab for systemic lupus erythematosus in Europe. <i>Lupus Science and Medicine</i> , <b>2016</b> , 3, e000163	4.6	34
331	How immunological profile drives clinical phenotype of primary Sjögren's syndrome at diagnosis: analysis of 10,500 patients (Sjögren Big Data Project). <i>Clinical and Experimental Rheumatology</i> , <b>2018</b> , 36 Suppl 112, 102-112	2.2	34
330	2016 American College of Rheumatology/European League Against Rheumatism Criteria for Minimal, Moderate, and Major Clinical Response in Adult Dermatomyositis and Polymyositis: An International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology International Trials Organisation Collaborative Initiative. <i>Arthritis and Rheumatology</i> , <b>2017</b> , 69, 898-910	9.5	33
329	B cell elimination in systemic lupus erythematosus. <i>Clinical Immunology</i> , <b>2013</b> , 146, 90-103	9	33
328	Autoantibodies against galectins are associated with antiphospholipid syndrome in patients with systemic lupus erythematosus. <i>Glycobiology</i> , <b>2013</b> , 23, 12-22	5.8	33
327	Mixed connective tissue disease: still crazy after all these years. <i>Rheumatic Disease Clinics of North America</i> , <b>2005</b> , 31, 421-36, v	2.4	33
326	Common patterns of B cell perturbation and expanded V4-34 immunoglobulin gene usage in autoimmunity and infection. <i>Autoimmunity</i> , <b>2004</b> , 37, 9-15	3	32
325	Electrocardiographic findings in systemic lupus erythematosus: data from an international inception cohort. <i>Arthritis Care and Research</i> , <b>2015</b> , 67, 128-35	4.7	31
324	Numerical scoring for the Classic BILAG index. <i>Rheumatology</i> , <b>2009</b> , 48, 1548-52	3.9	31
323	Zinc is an essential cofactor for recognition of the DNA binding domain of poly(ADP-ribose) polymerase by antibodies in autoimmune rheumatic and bowel diseases. <i>Arthritis and Rheumatism</i> , <b>1998</b> , 41, 918-26		31
322	Elevated levels of the 90 kD heat shock protein in patients with systemic lupus erythematosus are dependent upon enhanced transcription of the hsp90 beta gene. <i>Journal of Autoimmunity</i> , <b>1993</b> , 6, 495-506	15.5	31
321	Psychosis in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study. <i>Arthritis and Rheumatology</i> , <b>2019</b> , 71, 281-289	9.5	31
320	Defining response in systemic lupus erythematosus: a study by the Systemic Lupus International Collaborating Clinics group. <i>Journal of Rheumatology</i> , <b>2004</b> , 31, 2390-4	4.1	31
319	Intracellular B Lymphocyte Signalling and the Regulation of Humoral Immunity and Autoimmunity. <i>Clinical Reviews in Allergy and Immunology</i> , <b>2017</b> , 53, 237-264	12.3	30
318	Concomitant diseases in a cohort of patients with idiopathic myositis during long-term follow-up. <i>Clinical Rheumatology</i> , <b>2009</b> , 28, 947-53	3.9	30
317	A novel expression system of domain I of human beta2 glycoprotein I in Escherichia coli. <i>BMC Biotechnology</i> , <b>2006</b> , 6, 8	3.5	30
316	A systematic analysis of sequences of human antiphospholipid and anti-beta2-glycoprotein I antibodies: the importance of somatic mutations and certain sequence motifs. <i>Seminars in Arthritis and Rheumatism</i> , <b>2003</b> , 32, 246-65	5.3	30

315	Anti-prothrombin antibodies: assay conditions and clinical associations in the anti-phospholipid syndrome. <i>British Journal of Haematology</i> , <b>2001</b> , 113, 544-9	4.5	30
314	Crossreactivity of human anti-dsDNA antibodies to phosphorylcholine: clues to their origin. <i>Journal of Autoimmunity</i> , <b>2001</b> , 16, 479-84	15.5	30
313	Dual recognition of lipid A and DNA by human antibodies encoded by the VH4-21 gene: A possible link between infection and lupus. <i>Human Antibodies</i> , <b>1995</b> , 6, 52-56	1.3	30
312	Use of direct oral anticoagulants in patients with thrombotic antiphospholipid syndrome: Guidance from the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. <i>Journal of Thrombosis and Haemostasis</i> , <b>2020</b> , 18, 2126-2137	15.4	30
311	The importance of somatic mutations in the V(lambda) gene 2a2 in human monoclonal anti-DNA antibodies. <i>Journal of Molecular Biology</i> , <b>2001</b> , 307, 149-60	6.5	29
310	Autoantibodies to 90 kD heat-shock protein in sera of breast cancer patients. <i>Lancet, The</i> , <b>1995</b> , 345, 126	4.0	29
309	A review of serological abnormalities in relatives of SLE patients. <i>Lupus</i> , <b>1993</b> , 2, 145-50	2.6	29
308	Bcl-2 and Fas, molecules which influence apoptosis. A possible role in systemic lupus erythematosus?. <i>Autoimmunity</i> , <b>1994</b> , 17, 271-8	3	29
307	Decreased live births in women with systemic lupus erythematosus. <i>Arthritis Care and Research</i> , <b>2011</b> , 63, 1068-72	4.7	28
306	Imaging in CNS lupus. <i>Best Practice and Research in Clinical Rheumatology</i> , <b>2005</b> , 19, 727-39	5.3	28
305	Apoptosis in human autoimmune diseases. <i>International Reviews of Immunology</i> , <b>1999</b> , 18, 563-89	4.6	28
304	Cross-talk between iNKT cells and monocytes triggers an atheroprotective immune response in SLE patients with asymptomatic plaque. <i>Science Immunology</i> , <b>2016</b> , 1,	28	28
303	Arginine residues are important in determining the binding of human monoclonal antiphospholipid antibodies to clinically relevant antigens. <i>Journal of Immunology</i> , <b>2006</b> , 177, 1729-36	5.3	27
302	Autoantibodies against a nuclear 56 kDa protein: a marker for inflammatory muscle disease. <i>Journal of Autoimmunity</i> , <b>1989</b> , 2, 877-88	15.5	27
301	16th International Congress on Antiphospholipid Antibodies Task Force Report on Antiphospholipid Syndrome Treatment Trends. <i>Lupus</i> , <b>2020</b> , 29, 1571-1593	2.6	27
300	A Longitudinal Analysis of Outcomes of Lupus Nephritis in an International Inception Cohort Using a Multistate Model Approach. <i>Arthritis and Rheumatology</i> , <b>2016</b> , 68, 1932-44	9.5	27
299	Assessment of Response to B-Cell Depletion Using Rituximab in Cutaneous Lupus Erythematosus. <i>JAMA Dermatology</i> , <b>2018</b> , 154, 1432-1440	5.1	27
298	Assessment of disease activity, damage and quality of life in systemic lupus erythematosus: new aspects. <i>Best Practice and Research in Clinical Rheumatology</i> , <b>2013</b> , 27, 309-18	5.3	26

297	Post Hoc Analysis of the Phase II/III APRIL-SLE Study: Association Between Response to Atacicept and Serum Biomarkers Including BlyS and APRIL. <i>Arthritis and Rheumatology</i> , <b>2017</b> , 69, 122-130	9.5	26
296	Immunoglobulin variable region sequences of human monoclonal anti-DNA antibodies. <i>Seminars in Arthritis and Rheumatism</i> , <b>1998</b> , 28, 141-54	5.3	26
295	Autoantibody repertoire to Ro/SSA and La/SSB antigens in patients with primary and secondary Sjögren's syndrome. <i>Journal of Autoimmunity</i> , <b>1996</b> , 9, 537-44	15.5	26
294	HLA association of anti-Ro60 and anti-Ro52 antibodies in Sjögren's syndrome. <i>Journal of Autoimmunity</i> , <b>1994</b> , 7, 611-21	15.5	26
293	A common anti-DNA antibody idiotype and anti-phospholipid antibodies in sera from patients with schistosomiasis and filariasis with and without nephritis. <i>Journal of Autoimmunity</i> , <b>1989</b> , 2, 803-11	15.5	26
292	Anti-dsDNA antibodies: still a useful criterion for patients with systemic lupus erythematosus?. <i>Lupus</i> , <b>2004</b> , 13, 881-5	2.6	25
291	Relative importance of different human aPL derived heavy and light chains in the binding of aPL to cardiolipin. <i>Molecular Immunology</i> , <b>2003</b> , 40, 49-60	4.3	25
290	Elevation of IL-6 in transgenic mice results in increased levels of the 90 kDa heat shock protein (hsp90) and the production of anti-hsp90 antibodies. <i>Journal of Autoimmunity</i> , <b>1998</b> , 11, 249-53	15.5	25
289	A Prospective International Study on Adherence to Treatment in 305 Patients With Flaring SLE: Assessment by Drug Levels and Self-Administered Questionnaires. <i>Clinical Pharmacology and Therapeutics</i> , <b>2018</b> , 103, 1074-1082	6.1	24
288	Systemic Lupus International Collaborating Group--onwards and upwards?. <i>Lupus</i> , <b>2006</b> , 15, 606-7	2.6	24
287	The origin and significance of anti-DNA antibodies. <i>Trends in Immunology</i> , <b>1987</b> , 8, 279-82		24
286	Epidemiological profile and north-south gradient driving baseline systemic involvement of primary Sjögren's syndrome. <i>Rheumatology</i> , <b>2020</b> , 59, 2350-2359	3.9	24
285	The use of rituximab in newly diagnosed patients with systemic lupus erythematosus: long-term steroid saving capacity and clinical effectiveness. <i>Lupus Science and Medicine</i> , <b>2017</b> , 4, e000182	4.6	23
284	B-cell survival factors in autoimmune rheumatic disorders. <i>Therapeutic Advances in Musculoskeletal Disease</i> , <b>2015</b> , 7, 122-51	3.8	23
283	Smoking Is the Most Significant Modifiable Lung Cancer Risk Factor in Systemic Lupus Erythematosus. <i>Journal of Rheumatology</i> , <b>2018</b> , 45, 393-396	4.1	23
282	The British Society for Rheumatology guideline for the management of systemic lupus erythematosus in adults: Executive Summary. <i>Rheumatology</i> , <b>2018</b> , 57, 14-18	3.9	23
281	Serum rituximab levels and efficiency of B cell depletion: differences between patients with rheumatoid arthritis and systemic lupus erythematosus. <i>Rheumatology</i> , <b>2013</b> , 52, 951-2	3.9	23
280	Pathology of systemic lupus erythematosus: the challenges ahead. <i>Methods in Molecular Biology</i> , <b>2014</b> , 1134, 1-16	1.4	23

279	Vaccines and biologics. <i>Annals of the Rheumatic Diseases</i> , <b>2014</b> , 73, 1446-54	2.4	22
278	Profile of atacicept and its potential in the treatment of systemic lupus erythematosus. <i>Drug Design, Development and Therapy</i> , <b>2015</b> , 9, 1331-9	4.4	22
277	Primary Sjögren's syndrome activity and damage indices comparison. <i>European Journal of Clinical Investigation</i> , <b>2010</b> , 40, 636-44	4.6	22
276	Immunisation of patients with systemic lupus erythematosus: the current state of play. <i>Lupus</i> , <b>1999</b> , 8, 497-501	2.6	22
275	Belimumab in systemic lupus erythematosus (SLE): evidence-to-date and clinical usefulness. <i>Therapeutic Advances in Musculoskeletal Disease</i> , <b>2017</b> , 9, 75-85	3.8	21
274	The regulation of heat shock proteins and their role in systemic lupus erythematosus. <i>Seminars in Arthritis and Rheumatism</i> , <b>1998</b> , 28, 155-62	5.3	21
273	Use of a strategy based on calculated risk scores in managing cardiovascular risk factors in a large British cohort of patients with systemic lupus erythematosus. <i>Rheumatology</i> , <b>2009</b> , 48, 573-5	3.9	21
272	Thrombotic risk in patients submitted to splenectomy for systemic lupus erythematosus and antiphospholipid antibody syndrome-related thrombocytopenia. <i>European Journal of Internal Medicine</i> , <b>2004</b> , 15, 162-167	3.9	21
271	The role of hsp90 in SLE. <i>Autoimmunity</i> , <b>1994</b> , 19, 211-8	3	21
270	Pancreatic disease in the autoimmune rheumatic disorders. <i>Seminars in Arthritis and Rheumatism</i> , <b>1989</b> , 19, 158-65	5.3	21
269	Disease-associated and patient-specific immune cell signatures in juvenile-onset systemic lupus erythematosus: patient stratification using a machine-learning approach. <i>Lancet Rheumatology</i> , <b>2020</b> , 2, e485-e496	14.2	21
268	Belimumab after B cell depletion therapy in patients with systemic lupus erythematosus (BEAT Lupus) protocol: a prospective multicentre, double-blind, randomised, placebo-controlled, 52-week phase II clinical trial. <i>BMJ Open</i> , <b>2019</b> , 9, e032569	3	21
267	Construction of a Frailty Index as a Novel Health Measure in Systemic Lupus Erythematosus. <i>Journal of Rheumatology</i> , <b>2020</b> , 47, 72-81	4.1	21
266	IgG anti-apolipoprotein A-1 antibodies in patients with systemic lupus erythematosus are associated with disease activity and corticosteroid therapy: an observational study. <i>Arthritis Research and Therapy</i> , <b>2015</b> , 17, 26	5.7	20
265	Glucocorticoid use and factors associated with variability in this use in the Systemic Lupus International Collaborating Clinics Inception Cohort. <i>Rheumatology</i> , <b>2018</b> , 57, 677-687	3.9	20
264	A Prospective International Study on Adherence to Treatment in 305 Patients With Flaring SLE: Assessment by Drug Levels and Self-Administered Questionnaires. <i>Clinical Pharmacology and Therapeutics</i> , <b>2019</b> , 106, 374-382	6.1	20
263	B lymphocyte hyperactivity in families of patients with systemic lupus erythematosus. <i>Journal of Autoimmunity</i> , <b>1996</b> , 9, 59-65	15.5	20
262	B cell targeted therapies in autoimmune diseases. <i>Journal of rheumatology Supplement</i> , <b>2006</b> , 77, 24-8		20

261	Rituximab as an effective alternative therapy in refractory idiopathic inflammatory myopathies. <i>Clinical and Experimental Rheumatology</i> , <b>2013</b> , 31, 896-903	2.2	20
260	Do the EULAR Sjögren's syndrome outcome measures correlate with health status in primary Sjögren's syndrome?. <i>Rheumatology</i> , <b>2015</b> , 54, 655-9	3.9	19
259	Advances in the treatment of ocular dryness associated with Sjögren's syndrome. <i>Seminars in Arthritis and Rheumatism</i> , <b>2015</b> , 45, 321-7	5.3	19
258	Systemic lupus erythematosus--2005 annus mirabilis?. <i>Nature Clinical Practice Rheumatology</i> , <b>2006</b> , 2, 145-52		19
257	Autoimmunity associated with infection: leprosy, acute rheumatic fever and Lyme disease. <i>Current Opinion in Immunology</i> , <b>1991</b> , 3, 930-5	7.8	19
256	The endocrinologic associations of the autoimmune rheumatic diseases. <i>Seminars in Arthritis and Rheumatism</i> , <b>1987</b> , 17, 58-70	5.3	19
255	The role of antigen in autoimmune responses with special reference to changes in carbohydrate structure of IgG in rheumatoid arthritis. <i>Journal of Autoimmunity</i> , <b>1988</b> , 1, 499-506	15.5	19
254	Presence of anti-rituximab antibodies predicts infusion-related reactions in patients with systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , <b>2019</b> , 78, 1140-1142	2.4	18
253	Longer duration of B cell depletion is associated with better outcome. <i>Rheumatology</i> , <b>2015</b> , 54, 1876-81	3.9	18
252	The coming of age of adolescent rheumatology. <i>Nature Reviews Rheumatology</i> , <b>2014</b> , 10, 187-93	8.1	18
251	Long-term improvement of lipid profile in patients with refractory systemic lupus erythematosus treated with B-cell depletion therapy: a retrospective observational study. <i>Rheumatology</i> , <b>2010</b> , 49, 691-6	3.9	18
250	Thrombin binding predicts the effects of sequence changes in a human monoclonal antiphospholipid antibody on its in vivo biologic actions. <i>Journal of Immunology</i> , <b>2009</b> , 182, 4836-43	5.3	18
249	Interrater reliability and aspects of validity of the myositis damage index. <i>Annals of the Rheumatic Diseases</i> , <b>2011</b> , 70, 1272-6	2.4	18
248	Expression of the Fabs of human auto-antibodies in Escherichia coli: optimization and determination of their fine binding characteristics and cross-reactivity. <i>Journal of Molecular Biology</i> , <b>2001</b> , 308, 527-39	6.5	18
247	DNA antibody idiotypes: an analysis of their clinical connections and origins. <i>International Reviews of Immunology</i> , <b>1990</b> , 5, 279-93	4.6	18
246	Idiotypes and autoimmunity: a review of their role in human disease. <i>Journal of Autoimmunity</i> , <b>1988</b> , 1, 7-30	15.5	18
245	Neuropsychiatric events in systemic lupus erythematosus: a longitudinal analysis of outcomes in an international inception cohort using a multistate model approach. <i>Annals of the Rheumatic Diseases</i> , <b>2020</b> , 79, 356-362	2.4	18
244	Peripheral Nervous System Disease in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study. <i>Arthritis and Rheumatology</i> , <b>2020</b> , 72, 67-77	9.5	18



243	Bruton <sup>®</sup> Tyrosine Kinase Inhibitors: A New Therapeutic Target for the Treatment of SLE?. <i>ImmunoTargets and Therapy</i> , <b>2020</b> , 9, 105-110	9	17
242	American College of Rheumatology criteria at inception, and accrual over 5 years in the SLICC inception cohort. <i>Journal of Rheumatology</i> , <b>2014</b> , 41, 875-80	4.1	17
241	Invariant natural killer T cells are enriched at the site of cutaneous inflammation in lupus erythematosus. <i>Journal of Dermatological Science</i> , <b>2013</b> , 71, 22-8	4.3	17
240	Second-line agents in myositis: 1-year factorial trial of additional immunosuppression in patients who have partially responded to steroids. <i>Rheumatology</i> , <b>2015</b> , 54, 1050-5	3.9	17
239	Rituximab-it was the best of times, it was the worst of times. <i>Autoimmunity Reviews</i> , <b>2012</b> , 11, 790-1	13.6	17
238	Immunopathogenesis of SLE. <i>Baillieres Clinical Rheumatology</i> , <b>1998</b> , 12, 385-403		17
237	The critical role of arginine residues in the binding of human monoclonal antibodies to cardiolipin. <i>Arthritis Research</i> , <b>2005</b> , 7, R47-56		17
236	Molecular cloning and expression of the Fabs of human autoantibodies in Escherichia coli. Determination of the heavy or light chain contribution to the anti-DNA/-cardiolipin activity of the Fab. <i>Journal of Biological Chemistry</i> , <b>2000</b> , 275, 35129-36	5.4	17
235	Assessment of long-term remission in lupus nephritis patients: a retrospective analysis over 30 years. <i>Rheumatology</i> , <b>2015</b> , 54, 1403-7	3.9	16
234	Why and how should we measure disease activity and damage in lupus?. <i>Presse Medicale</i> , <b>2014</b> , 43, e151-6.2		16
233	Endothelial microparticle release is stimulated in vitro by purified IgG from patients with the antiphospholipid syndrome. <i>Thrombosis and Haemostasis</i> , <b>2013</b> , 109, 72-8	7	16
232	Cross-reaction of lupus anti-dsDNA antibodies with protein translation factor EF-2. <i>Clinical Immunology</i> , <b>2001</b> , 98, 293-300	9	16
231	Myositis overlap syndromes. <i>Current Opinion in Rheumatology</i> , <b>1999</b> , 11, 468-474	5.3	16
230	Comparison of Three Classification Criteria Sets for Systemic Lupus Erythematosus: A Study Looking at Links to Outcome and Mortality. <i>Arthritis Care and Research</i> , <b>2020</b> , 72, 1611-1614	4.7	16
229	An evaluation of voclosporin for the treatment of lupus nephritis. <i>Expert Opinion on Pharmacotherapy</i> , <b>2018</b> , 19, 1613-1621	4	16
228	Evaluating the Properties of a Frailty Index and Its Association With Mortality Risk Among Patients With Systemic Lupus Erythematosus. <i>Arthritis and Rheumatology</i> , <b>2019</b> , 71, 1297-1307	9.5	15
227	Towards Precision Medicine in Systemic Lupus Erythematosus. <i>Pharmacogenomics and Personalized Medicine</i> , <b>2020</b> , 13, 39-49	2.1	15
226	Screening autoantibody profiles in systemic rheumatic disease with a diagnostic protein microarray that uses a filtration-assisted nanodot array luminometric immunoassay (NALIA). <i>Clinical Chemistry</i> , <b>2008</b> , 54, 883-90	5.5	15

225	Systemic lupus erythematosus measures: British Isles Lupus Assessment Group (BILAG), European Consensus Lupus Activity Measurement (ECLAM), Systemic Lupus Activity Measure (SLAM), Systemic Lupus Erythematosus Disease Activity Measure (SLEDAI), and Systemic Lupus International Collaborating Clinics/American College of Rheumatology-Damage Index		15
224	Somatic mutations to arginine residues affect the binding of human monoclonal antibodies to DNA, histones, SmD and Ro antigen. <i>Molecular Immunology</i> , <b>2004</b> , 40, 745-58	4.3	15
223	Soluble urokinase plasminogen activator receptor (suPAR) levels predict damage accrual in patients with recent-onset systemic lupus erythematosus. <i>Journal of Autoimmunity</i> , <b>2020</b> , 106, 102340	15.5	15
222	Belimumab in systemic lupus erythematosus. <i>RMD Open</i> , <b>2015</b> , 1, e000011	5.9	14
221	Changes in regulation of human monocyte proteins in response to IgG from patients with antiphospholipid syndrome. <i>Blood</i> , <b>2014</b> , 124, 3808-16	2.2	14
220	Autoantibodies against C1q as a Diagnostic Measure of Lupus Nephritis: Systematic Review and Meta-analysis. <i>Journal of Clinical &amp; Cellular Immunology</i> , <b>2014</b> , 5, 210	2.7	14
219	Evaluating the conformation of recombinant domain I of $\beta_2$ -glycoprotein I and its interaction with human monoclonal antibodies. <i>Molecular Immunology</i> , <b>2011</b> , 49, 56-63	4.3	14
218	Systemic lupus erythematosus: pharmacological developments and recommendations for a therapeutic strategy. <i>Expert Opinion on Investigational Drugs</i> , <b>2008</b> , 17, 31-41	5.9	14
217	Can we validate a clinical score to predict the risk of severe infection in patients with systemic lupus erythematosus? A longitudinal retrospective study in a British Cohort. <i>BMJ Open</i> , <b>2019</b> , 9, e028697		13
216	A reverse translational study on the effect of rituximab, rituximab plus belimumab, or bortezomib on the humoral autoimmune response in SLE. <i>Rheumatology</i> , <b>2020</b> , 59, 2734-2745	3.9	13
215	Gene expression profiling identifies distinct molecular signatures in thrombotic and obstetric antiphospholipid syndrome. <i>Journal of Autoimmunity</i> , <b>2018</b> , 93, 114-123	15.5	13
214	Green tea polyphenol epigallocatechin gallate inhibits cell signaling by inducing SOCS1 gene expression. <i>International Immunology</i> , <b>2010</b> , 22, 359-66	4.9	13
213	Assessment of patients with primary Sjögren's syndrome--outcome over 10 years using the Sjögren's Syndrome Damage Index. <i>Rheumatology</i> , <b>2010</b> , 49, 1559-62	3.9	13
212	Sjögren's syndrome: diagnosis and therapeutic challenges in the elderly. <i>Drugs and Aging</i> , <b>2008</b> , 25, 19-33	4.7	13
211	Familial clustering of non-nuclear autoantibodies and C3 and C4 complement components in systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , <b>2008</b> , 58, 1116-24		13
210	Stable expression of a recombinant human antinucleosome antibody to investigate relationships between antibody sequence, binding properties, and pathogenicity. <i>Arthritis Research and Therapy</i> , <b>2005</b> , 7, R971-83	5.7	13
209	Under crossfire: thromboembolic risk in systemic lupus erythematosus. <i>Rheumatology</i> , <b>2019</b> , 58, 940-952	3.9	13
208	Economic Evaluation of Lupus Nephritis in the Systemic Lupus International Collaborating Clinics Inception Cohort Using a Multistate Model Approach. <i>Arthritis Care and Research</i> , <b>2018</b> , 70, 1294-1302	4.7	13

207	Why do patients with myositis die? A retrospective analysis of a single-centre cohort. <i>Clinical and Experimental Rheumatology</i> , <b>2016</b> , 34, 820-826	2.2	13
206	Attainment of treat-to-target endpoints in SLE patients with high disease activity in the atacicept phase 2b ADDRESS II study. <i>Rheumatology</i> , <b>2020</b> , 59, 2930-2938	3.9	12
205	Differential Treatments Based on Drug-induced Gene Expression Signatures and Longitudinal Systemic Lupus Erythematosus Stratification. <i>Scientific Reports</i> , <b>2019</b> , 9, 15502	4.9	12
204	Recent developments in the treatment of patients with systemic lupus erythematosus: focusing on biologic therapies. <i>Expert Opinion on Biological Therapy</i> , <b>2014</b> , 14, 311-26	5.4	12
203	Impaired C3b/iC3b deposition on Streptococcus pneumoniae in serum from patients with systemic lupus erythematosus. <i>Rheumatology</i> , <b>2009</b> , 48, 1498-501	3.9	12
202	Treating patients with lupus with B-cell depletion. <i>Lupus</i> , <b>2008</b> , 17, 400-4	2.6	12
201	Sequences of monoclonal antiphospholipid antibodies: variations on an anti-DNA antibody theme. <i>Seminars in Arthritis and Rheumatism</i> , <b>1996</b> , 26, 515-25	5.3	12
200	The use of hybridomas to analyse autoimmunity. <i>British Medical Bulletin</i> , <b>1984</b> , 40, 262-6	5.4	12
199	Recent developments in biologic therapies for the treatment of patients with systemic lupus erythematosus. <i>Rheumatology</i> , <b>2019</b> , 58, 382-387	3.9	12
198	Thrombotic antiphospholipid syndrome: A practical guide to diagnosis and management. <i>Thrombosis Research</i> , <b>2021</b> , 198, 213-221	8.2	12
197	How COVID-19 is changing rheumatology clinical practice. <i>Nature Reviews Rheumatology</i> , <b>2021</b> , 17, 11-15	5.1	12
196	Musculoskeletal complications of haematological disease. <i>Rheumatology</i> , <b>2016</b> , 55, 968-81	3.9	11
195	Anti-factor Xa antibodies in patients with antiphospholipid syndrome and their effects upon coagulation assays. <i>Arthritis Research and Therapy</i> , <b>2015</b> , 17, 47	5.7	11
194	Mixed connective tissue disease-enigma variations?. <i>Rheumatology</i> , <b>2017</b> , 56, 326-333	3.9	11
193	Rituximab: the Lupus Journey. <i>Current Treatment Options in Rheumatology</i> , <b>2015</b> , 1, 30-41	1.3	11
192	The BILAG-2004 systems tally--a novel way of representing the BILAG-2004 index scores longitudinally. <i>Rheumatology</i> , <b>2012</b> , 51, 2099-105	3.9	11
191	Interactions of human monoclonal and polyclonal antiphospholipid antibodies with serine proteases involved in hemostasis. <i>Arthritis and Rheumatism</i> , <b>2011</b> , 63, 3512-21		11
190	Autoantibodies: markers of disease or pathogenic?. <i>Annals of the New York Academy of Sciences</i> , <b>1997</b> , 823, 256-62	6.5	11

189	Arginine mutation alters binding of a human monoclonal antibody to antigens linked to systemic lupus erythematosus and the antiphospholipid syndrome. <i>Arthritis and Rheumatism</i> , <b>2007</b> , 56, 2392-401		11
188	The origin and pathogenic consequences of anti-dsDNA antibodies in systemic lupus erythematosus. <i>Expert Review of Clinical Immunology</i> , <b>2006</b> , 2, 377-85	5.1	11
187	Spontaneous antibody-secreting cells against DNA and common environmental antigens in systemic lupus erythematosus. <i>Journal of Autoimmunity</i> , <b>1990</b> , 3, 523-30	15.5	11
186	Prediction of Damage Accrual in Systemic Lupus Erythematosus Using the Systemic Lupus International Collaborating Clinics Frailty Index. <i>Arthritis and Rheumatology</i> , <b>2020</b> , 72, 658-666	9.5	11
185	Increased apolipoprotein-B:A1 ratio predicts cardiometabolic risk in patients with juvenile onset SLE. <i>EBioMedicine</i> , <b>2021</b> , 65, 103243	8.8	11
184	Efficacy, Safety, and Pharmacodynamic Effects of the Bruton <sup>®</sup> Tyrosine Kinase Inhibitor Fenebrutinib (GDC-0853) in Systemic Lupus Erythematosus: Results of a Phase II, Randomized, Double-Blind, Placebo-Controlled Trial. <i>Arthritis and Rheumatology</i> , <b>2021</b> , 73, 1835-1846	9.5	11
183	Physical activity but not sedentary activity is reduced in primary Sjögren <sup>®</sup> syndrome. <i>Rheumatology International</i> , <b>2017</b> , 37, 623-631	3.6	10
182	Comparison of the 2019 European Alliance of Associations for Rheumatology/American College of Rheumatology Systemic Lupus Erythematosus Classification Criteria With Two Sets of Earlier Systemic Lupus Erythematosus Classification Criteria. <i>Arthritis Care and Research</i> , <b>2021</b> , 73, 1231-1235	4.7	10
181	Direct Oral Anticoagulants for Thromboprophylaxis in Patients with Antiphospholipid Syndrome. <i>Seminars in Thrombosis and Hemostasis</i> , <b>2018</b> , 44, 427-438	5.3	10
180	Damage accrual and mortality over long-term follow-up in 300 patients with systemic lupus erythematosus in a multi-ethnic British cohort. <i>Rheumatology</i> , <b>2020</b> , 59, 524-533	3.9	10
179	The Systemic Lupus International Collaborating Clinics (SLICC) group - it was 20 years ago today. <i>Lupus</i> , <b>2011</b> , 20, 1426-32	2.6	10
178	Agrin signalling contributes to cell activation and is overexpressed in T lymphocytes from lupus patients. <i>Journal of Immunology</i> , <b>2007</b> , 179, 7975-83	5.3	10
177	Comparison of a monoclonal and polyclonal anti-idiotypic against a human IgG anti-DNA antibody. <i>Journal of Autoimmunity</i> , <b>1994</b> , 7, 349-67	15.5	10
176	Present and novel biologic drugs in primary Sjögren <sup>®</sup> syndrome. <i>Clinical and Experimental Rheumatology</i> , <b>2019</b> , 37 Suppl 118, 167-174	2.2	10
175	Pain and depression are associated with both physical and mental fatigue independently of comorbidities and medications in primary Sjögren <sup>®</sup> syndrome. <i>RMD Open</i> , <b>2019</b> , 5, e000885	5.9	9
174	From BILAG to BILAG-based combined lupus assessment-30 years on. <i>Rheumatology</i> , <b>2016</b> , 55, 1357-63	3.9	9
173	Systemic lupus erythematosus in 2013. Taking a closer look at biologic therapy for SLE. <i>Nature Reviews Rheumatology</i> , <b>2014</b> , 10, 71-2	8.1	9
172	Improving B-cell depletion in systemic lupus erythematosus and rheumatoid arthritis. <i>Expert Review of Clinical Immunology</i> , <b>2017</b> , 13, 667-676	5.1	9

171	A negatively charged domain of LAT mediates its interaction with the active form of Lck. <i>Molecular Membrane Biology</i> , <b>2011</b> , 28, 487-94	3.4	9
170	Lupus nephritis: assessing the evidence, considering the future. <i>Lupus</i> , <b>2007</b> , 16, 210-1	2.6	9
169	Interleukin-10 promoter polymorphism and lupus nephritis: comment on the article by Mok et al. <i>Arthritis and Rheumatism</i> , <b>1999</b> , 42, 590-3		9
168	Risk factors for renal disease in systemic lupus erythematosus and their clinical implications. <i>Expert Review of Clinical Immunology</i> , <b>2015</b> , 11, 837-48	5.1	8
167	Clinical trial parameters that influence outcomes in lupus trials that use the systemic lupus erythematosus responder index. <i>Rheumatology</i> , <b>2018</b> , 57, 125-133	3.9	8
166	B-lymphocyte signalling abnormalities and lupus immunopathology. <i>International Reviews of Immunology</i> , <b>2013</b> , 32, 428-44	4.6	8
165	Treatment of rheumatoid arthritis is good medicine. <i>BMJ, The</i> , <b>2011</b> , 343, d6962; author reply d7052	5.9	8
164	Treating lupus: from serendipity to sense, the rise of the new biologicals and other emerging therapies. <i>Best Practice and Research in Clinical Rheumatology</i> , <b>2009</b> , 23, 563-74	5.3	8
163	Naming names! Comment on the article by Smolen and Steiner. <i>Arthritis and Rheumatism</i> , <b>1999</b> , 42, 191-6		8
162	Effectiveness of Belimumab After Rituximab in Systemic Lupus Erythematosus : A Randomized Controlled Trial. <i>Annals of Internal Medicine</i> , <b>2021</b> ,	8	8
161	PEGylated Domain I of Beta-2-Glycoprotein I Inhibits the Binding, Coagulopathic, and Thrombogenic Properties of IgG From Patients With the Antiphospholipid Syndrome. <i>Frontiers in Immunology</i> , <b>2018</b> , 9, 2413	8.4	8
160	Antiphospholipid Antibodies to Domain I of Beta-2-Glycoprotein I Show Different Subclass Predominance in Comparison to Antibodies to Whole Beta-2-glycoprotein I. <i>Frontiers in Immunology</i> , <b>2018</b> , 9, 2244	8.4	8
159	Adverse infusion reactions to rituximab in systemic lupus erythematosus: a retrospective analysis. <i>BMC Rheumatology</i> , <b>2019</b> , 3, 32	2.9	7
158	Osteopontin and Disease Activity in Patients with Recent-onset Systemic Lupus Erythematosus: Results from the SLICC Inception Cohort. <i>Journal of Rheumatology</i> , <b>2019</b> , 46, 492-500	4.1	7
157	Eligibility for clinical trials in primary Sjögren's syndrome: lessons from the UK Primary Sjögren's Syndrome Registry. <i>Rheumatology</i> , <b>2016</b> , 55, 544-52	3.9	7
156	Accrual of Atherosclerotic Vascular Events in a Multicenter Inception Systemic Lupus Erythematosus Cohort. <i>Arthritis and Rheumatology</i> , <b>2020</b> , 72, 1734-1740	9.5	7
155	Comment on: The British Society for Rheumatology guideline for the management of systemic lupus erythematosus in adults: reply. <i>Rheumatology</i> , <b>2018</b> , 57, 1502-1503	3.9	7
154	Anti-cardiolipin/beta-2 glycoprotein activities co-exist on human anti-DNA antibody light chains. <i>Molecular Immunology</i> , <b>2003</b> , 40, 517-30	4.3	7

153	Elevated levels of the 70 kD heat shock protein in patients with systemic lupus erythematosus are not dependent on enhanced transcription of the hsp70 gene. <i>Lupus</i> , <b>1993</b> , 2, 297-301	2.6	7
152	Transcription of the genes encoding the small heat shock protein ubiquitin is unchanged in patients with systemic lupus erythematosus. <i>Autoimmunity</i> , <b>1992</b> , 13, 197-200	3	7
151	2021 DORIS definition of remission in SLE: final recommendations from an international task force. <i>Lupus Science and Medicine</i> , <b>2021</b> , 8,	4.6	7
150	Economic Evaluation of Damage Accrual in an International Systemic Lupus Erythematosus Inception Cohort Using a Multistate Model Approach. <i>Arthritis Care and Research</i> , <b>2020</b> , 72, 1800-1808	4.7	7
149	Measures of Adult Systemic Lupus Erythematosus: Disease Activity and Damage. <i>Arthritis Care and Research</i> , <b>2020</b> , 72 Suppl 10, 27-46	4.7	7
148	How I treat anticoagulant-refractory thrombotic antiphospholipid syndrome. <i>Blood</i> , <b>2021</b> , 137, 299-309	2.2	7
147	Advances in systemic lupus erythematosus. <i>Medicine</i> , <b>2018</b> , 46, 84-92	0.6	6
146	Current pharmacological treatment of idiopathic inflammatory myopathies. <i>Expert Review of Clinical Pharmacology</i> , <b>2016</b> , 9, 547-558	3.8	6
145	Aberrant B-lymphocyte responses in lupus: inherent or induced and potential therapeutic targets. <i>European Journal of Clinical Investigation</i> , <b>2013</b> , 43, 866-80	4.6	6
144	Idiotypic manipulation for autoimmune diseases: where are we going?. <i>Autoimmunity</i> , <b>1996</b> , 24, 55-63	3	6
143	Lupus autoantibodies to native DNA preferentially bind DNA presented on PolIV. <i>Immunology</i> , <b>2005</b> , 114, 418-27	7.8	6
142	Sequence analysis and fine specificity of two human monoclonal antibodies to histone H1. <i>Molecular Immunology</i> , <b>1994</b> , 31, 269-77	4.3	6
141	Autoantibodies in systemic lupus erythematosus. <i>Current Opinion in Rheumatology</i> , <b>1994</b> , 6, 468-73	5.3	6
140	The rheumatologic complications of hematologic disorders. <i>Seminars in Arthritis and Rheumatism</i> , <b>1983</b> , 12, 348-58	5.3	6
139	Ultrasound to identify systemic lupus erythematosus patients with musculoskeletal symptoms who respond best to therapy: the US Evaluation For musculoskeletal Lupus longitudinal multicentre study. <i>Rheumatology</i> , <b>2021</b> , 60, 5194-5204	3.9	6
138	Comment on the 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus by Fanouriakis. <i>Annals of the Rheumatic Diseases</i> , <b>2020</b> , 79, e90	2.4	6
137	Antiphospholipid antibody levels in early systemic lupus erythematosus: are they associated with subsequent mortality and vascular events?. <i>Rheumatology</i> , <b>2020</b> , 59, 146-152	3.9	6
136	Low Percentage of Signal Regulatory Protein $\alpha$ Memory B Cells in Blood Predicts Development of Anti-drug Antibodies (ADA) in Adalimumab-Treated Rheumatoid Arthritis Patients. <i>Frontiers in Immunology</i> , <b>2018</b> , 9, 2865	8.4	6

135	Use of combined hormonal contraceptives among women with systemic lupus erythematosus with and without medical contraindications to oestrogen. <i>Rheumatology</i> , <b>2019</b> , 58, 1259-1267	3.9	5
134	"Mixed connective tissue disease": a condition in search of an identity. <i>Clinical and Experimental Medicine</i> , <b>2020</b> , 20, 159-166	4.9	5
133	Impact of pre-transplant time on dialysis on survival in patients with lupus nephritis. <i>Clinical Rheumatology</i> , <b>2018</b> , 37, 2399-2404	3.9	5
132	Using peripheral blood immune signatures to stratify patients with adult and juvenile inflammatory myopathies. <i>Rheumatology</i> , <b>2020</b> , 59, 194-204	3.9	5
131	Advances in systemic lupus erythematosus. <i>Medicine</i> , <b>2014</b> , 42, 126-133	0.6	5
130	Factor Xa Mediates Calcium Flux in Endothelial Cells and is Potentiated by Igg From Patients With Lupus and/or Antiphospholipid Syndrome. <i>Scientific Reports</i> , <b>2017</b> , 7, 10788	4.9	5
129	Direct Oral Anticoagulants Use in Antiphospholipid Syndrome: Are These Drugs an Effective and Safe Alternative to Warfarin? A Systematic Review of the Literature: Comment. <i>Current Rheumatology Reports</i> , <b>2017</b> , 19, 50	4.9	5
128	Pathogenic autoantibodies from patients with lupus nephritis cause reduced tyrosine phosphorylation of podocyte proteins, including tubulin. <i>Lupus Science and Medicine</i> , <b>2014</b> , 1, e000013	4.6	5
127	Thirty years, five hundred patients: some lessons learned from running a lupus clinic. <i>Lupus</i> , <b>2010</b> , 19, 667-74	2.6	5
126	p185, an immunodominant epitope, is an autoantigen mimotope. <i>Journal of Biological Chemistry</i> , <b>2011</b> , 286, 26220-7	5.4	5
125	Analysis of factors affecting human hybridoma production. <i>Human Antibodies</i> , <b>1990</b> , 1, 160-165	1.3	5
124	An analysis of autoimmunity through studies of DNA antibody idiotypes. <i>Autoimmunity</i> , <b>1988</b> , 1, 67-75	3	5
123	Use of direct oral anticoagulants in antiphospholipid syndrome: Reply. <i>Journal of Thrombosis and Haemostasis</i> , <b>2020</b> , 18, 259-261	15.4	5
122	The use of anti-TNF-alpha therapies for patients with systemic lupus erythematosus. Where are we now?. <i>Expert Opinion on Biological Therapy</i> , <b>2021</b> , 21, 639-647	5.4	5
121	Lower vitamin D is associated with metabolic syndrome and insulin resistance in systemic lupus: data from an international inception cohort. <i>Rheumatology</i> , <b>2021</b> , 60, 4737-4747	3.9	5
120	Differential levels of IFN $\gamma$ subtypes in autoimmunity and viral infection. <i>Cytokine</i> , <b>2021</b> , 144, 155533	4	5
119	Stratification of Patients With Sjögren's Syndrome and Patients With Systemic Lupus Erythematosus According to Two Shared Immune Cell Signatures, With Potential Therapeutic Implications. <i>Arthritis and Rheumatology</i> , <b>2021</b> , 73, 1626-1637	9.5	5
118	Impact of glucocorticoids on the incidence of lupus-related major organ damage: a systematic literature review and meta-regression analysis of longitudinal observational studies.. <i>Lupus Science and Medicine</i> , <b>2021</b> , 8,	4.6	5

117	Kidney disease in primary anti-phospholipid antibody syndrome. <i>Rheumatology</i> , <b>2017</b> , 56, 1069-1080	3.9	4
116	A case of repetitive myocardial infarction with unobstructed coronaries due to Churg-Strauss syndrome. <i>European Heart Journal - Case Reports</i> , <b>2019</b> , 3,	0.9	4
115	Serum nitrated nucleosome levels in patients with systemic lupus erythematosus: a retrospective longitudinal cohort study. <i>Arthritis Research and Therapy</i> , <b>2014</b> , 16, R48	5.7	4
114	Fine binding characteristics of human autoantibodies-partial molecular characterization. <i>Molecular Immunology</i> , <b>2004</b> , 41, 495-510	4.3	4
113	Assessment of inflammatory myositis. <i>Current Opinion in Rheumatology</i> , <b>2001</b> , 13, 488-92	5.3	4
112	Prevalence of Ro (SS-A) antibodies in patients with polymyositis. <i>Arthritis and Rheumatism</i> , <b>1987</b> , 30, 1320		4
111	Flares after hydroxychloroquine reduction or discontinuation: results from the Systemic Lupus International Collaborating Clinics (SLICC) inception cohort.. <i>Annals of the Rheumatic Diseases</i> , <b>2021</b>	2.4	4
110	Management of anticoagulant-refractory thrombotic antiphospholipid syndrome. <i>Lancet Haematology</i> , <b>2020</b> , 7, e613-e623	14.6	4
109	The safety of pharmacological treatment options for lupus nephritis. <i>Expert Opinion on Drug Safety</i> , <b>2016</b> , 15, 1041-54	4.1	4
108	Low aspirin use and high prevalence of pre-eclampsia risk factors among pregnant women in a multinational SLE inception cohort. <i>Annals of the Rheumatic Diseases</i> , <b>2019</b> , 78, 1010-1012	2.4	4
107	Anti-IFN $\beta$ Mabs for the treatment of systemic lupus erythematosus. <i>Expert Opinion on Biological Therapy</i> , <b>2021</b> , 21, 519-528	5.4	4
106	Anti-protein C antibodies and acquired protein C resistance in SLE: novel markers for thromboembolic events and disease activity?. <i>Rheumatology</i> , <b>2021</b> , 60, 1376-1386	3.9	4
105	Childhood-onset of primary Sjögren's syndrome: phenotypic characterization at diagnosis of 158 children. <i>Rheumatology</i> , <b>2021</b> , 60, 4558-4567	3.9	4
104	Why do some patients with systemic lupus erythematosus fail to respond to B-cell depletion using rituximab?. <i>Clinical and Experimental Rheumatology</i> , <b>2020</b> , 38, 262-266	2.2	4
103	What can we learn from systemic lupus erythematosus pathophysiology to improve current therapy?. <i>Expert Review of Clinical Immunology</i> , <b>2015</b> , 11, 1093-107	5.1	3
102	The role of in vitro expression systems in the investigation of antibodies to DNA. <i>Seminars in Arthritis and Rheumatism</i> , <b>1998</b> , 28, 130-9	5.3	3
101	Beta-2-glycoprotein specificity of human anti-phospholipid antibody resides on the light chain: a novel mechanism for acquisition of cross-reactivity by an autoantibody. <i>Molecular Immunology</i> , <b>2005</b> , 42, 39-48	4.3	3
100	Structure-function analysis and the molecular origins of anti-DNA antibodies in systemic lupus erythematosus. <i>Expert Reviews in Molecular Medicine</i> , <b>1999</b> , 1999, 1-28	6.7	3



99	Enhanced transcription of the gene encoding the SmN autoantigen in patients with systemic lupus erythematosus does not result in enhanced levels of the SmN protein. <i>Autoimmunity</i> , <b>1994</b> , 19, 81-7	3	3
98	Rivaroxaban Limits Complement Activation Compared to Warfarin in Antiphospholipid Syndrome Patients with Venous Thromboembolism. <i>Blood</i> , <b>2015</b> , 126, 2328-2328	2.2	3
97	The Expression of Heat Shock Proteins in Systemic Lupus Erythematosus <b>1994</b> , 99-129		3
96	Hydroxychloroquine in patients with rheumatic diseases during the COVID-19 pandemic: a letter to clinicians. <i>Lancet Rheumatology, The</i> , <b>2020</b> , 2, e735-e736	14.2	3
95	Outcomes of membranous and proliferative lupus nephritis - analysis of a single-centre cohort with more than 30 years of follow-up. <i>Rheumatology</i> , <b>2020</b> , 59, 3314-3323	3.9	3
94	Assessing outcomes in a lupus nephritis cohort over a 40-year period. <i>Rheumatology</i> , <b>2021</b> , 60, 1814-1823	3.9	3
93	Rituximab - The first twenty years. <i>Lupus</i> , <b>2021</b> , 30, 371-377	2.6	3
92	Review of major endocrine abnormalities in patients with systemic lupus erythematosus. <i>Clinical and Experimental Rheumatology</i> , <b>2019</b> , 37, 791-796	2.2	3
91	Prediction of hospitalizations in systemic lupus erythematosus using the Systemic Lupus International Collaborating Clinics Frailty Index (SLICC-FI). <i>Arthritis Care and Research</i> , <b>2020</b> ,	4.7	2
90	The assessment of patients with the antiphospholipid antibody syndrome: where are we now?. <i>Rheumatology</i> , <b>2020</b> , 59, 1489-1494	3.9	2
89	Reprint of: B cell elimination in systemic lupus erythematosus. Clin. Immunol. 146(2) 90-103. <i>Clinical Immunology</i> , <b>2013</b> , 148, 344-58	9	2
88	Pathogenesis of neurocognitive and neuropsychiatric manifestations in childhood-onset lupus: an overview. <i>Rheumatology Reports</i> , <b>2013</b> , 5, 6		2
87	Applicability of the paediatric rheumatology international trials organisation disease activity core set for juvenile dermatomyositis: comment on the article by Ruperto et al. <i>Arthritis and Rheumatism</i> , <b>2008</b> , 59, 1197-8; author reply 1198-9		2
86	Lessons from Sequence Analysis of Monoclonal Antiphospholipid Antibodies <b>2006</b> , 470-491		2
85	Neuroendocrine changes in systemic lupus erythematosus and Sjögren's syndrome. <i>Baillieres Clinical Rheumatology</i> , <b>1996</b> , 10, 333-47		2
84	Assessment of common idiotype PR4-Id in serial bleeds from lupus patients. <i>Autoimmunity</i> , <b>1991</b> , 9, 7-12		2
83	Does mitogen-induced antibody production by normal blood cells mimic spontaneous production in lupus?. <i>Autoimmunity</i> , <b>1992</b> , 13, 285-90	3	2
82	The Pathophysiology of Antiphospholipid Syndrome. <i>The Open Urology &amp; Nephrology Journal</i> , <b>2015</b> , 8, 2-9	0.2	2

81	Sex differences in autoimmunity could be associated with altered regulatory T cell phenotype and lipoprotein metabolism		2
80	Biologic therapies for systemic lupus erythematosus: where are we now?. <i>Current Opinion in Rheumatology</i> , <b>2020</b> , 32, 597-608	5.3	2
79	Fracture risk in systemic lupus erythematosus patients over 28 years. <i>Rheumatology</i> , <b>2021</b> , 60, 2765-2773.	3.9	2
78	Cancer Risk in a Large Inception Systemic Lupus Erythematosus Cohort: Effects of Demographic Characteristics, Smoking, and Medications. <i>Arthritis Care and Research</i> , <b>2021</b> , 73, 1789-1795	4.7	2
77	What Does It Mean to Be a British Isles Lupus Assessment Group-Based Composite Lupus Assessment Responder? Post Hoc Analysis of Two Phase III Trials. <i>Arthritis and Rheumatology</i> , <b>2021</b> , 73, 2059-2068	9.5	2
76	Anti-beta 2 glycoprotein I IgA in the SLICC classification criteria dataset. <i>Lupus</i> , <b>2021</b> , 30, 1283-1288	2.6	2
75	Neuropsychiatric Events in Systemic Lupus Erythematosus: Predictors of Occurrence and Resolution in a Longitudinal Analysis of an International Inception Cohort. <i>Arthritis and Rheumatology</i> , <b>2021</b> , 73, 2293-2302	9.5	2
74	Analysis of trends and causes of death in SLE patients over a 40-years period in a cohort of patients in the United Kingdom. <i>Lupus</i> , <b>2021</b> , 30, 702-706	2.6	2
73	Psychosis in systemic lupus erythematosus (SLE): 40-year experience of a specialist centre. <i>Rheumatology</i> , <b>2021</b> , 60, 5620-5629	3.9	2
72	Safety and clinical activity of atacicept in the long-term extension of the phase 2b ADDRESS II study in systemic lupus erythematosus. <i>Rheumatology</i> , <b>2021</b> , 60, 5379-5389	3.9	2
71	Can we predict if patients will require more than one cycle of rituximab?. <i>Rheumatology</i> , <b>2021</b> ,	3.9	2
70	Abnormalities in the glycosylation of IgG and its clinical utility. <i>Advances in Experimental Medicine and Biology</i> , <b>1995</b> , 376, 179-83	3.6	2
69	Use of autologous stem cell transplantation in adult patients with idiopathic inflammatory myopathies: a case-report and review of the literature. <i>Clinical and Experimental Rheumatology</i> , <b>2012</b> , 30, 979	2.2	2
68	E083 Designing a diet interventional study for autoimmune rheumatic disease: asking patients what they think. <i>Rheumatology</i> , <b>2019</b> , 58,	3.9	1
67	Characterization of a Subset of Patients With Rheumatoid Arthritis for Whom Current Management Strategies are Inadequate. <i>ACR Open Rheumatology</i> , <b>2019</b> , 1, 145-155	3.5	1
66	Clinical trials perception in rheumatology patients: experience from a single rheumatology tertiary center. <i>Journal of Rheumatology</i> , <b>2015</b> , 42, 988-93	4.1	1
65	Systemic lupus erythematosus: causes and manifestations. <i>Trends in Urology &amp; Men's Health</i> , <b>2020</b> , 11, 26-29	0.3	1
64	Very delayed lupus nephritis: a report of three cases and literature review. <i>Lupus Science and Medicine</i> , <b>2018</b> , 5, e000241	4.6	1

63	Overview of biologic therapies in autoimmune rheumatic diseases. <i>Medicine</i> , <b>2014</b> , 42, 184-187	0.6	1
62	A8.13 Changes in the relationship between BAFF, BAFF-R and B cell phenotype following rituximab in patients with systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , <b>2014</b> , 73, A81.1-A81	2.4	1
61	The potential overlapping populations for treatment with belimumab and rituximab using current NHS England and National Institute for Health and Care Excellence Guidelines in England and Wales. <i>Rheumatology</i> , <b>2017</b> , 56, 1041-1043	3.9	1
60	Nitrated nucleosome levels and neuropsychiatric events in systemic lupus erythematosus; a multi-center retrospective case-control study. <i>Arthritis Research and Therapy</i> , <b>2017</b> , 19, 287	5.7	1
59	324. LUPUS AND AVASCULAR NECROSIS OF THE BONE: HAS THE INCIDENCE IMPROVED?. <i>Rheumatology</i> , <b>2017</b> , 56,	3.9	1
58	Asymmetric appearance of immunological abnormalities in close relatives of patients with systemic lupus erythematosus. <i>Clinical Immunology</i> , <b>2015</b> , 157, 226-7	9	1
57	A3.27 Effect of rituximab on different isotypes of serum immunoglobulins in patients with SLE. <i>Annals of the Rheumatic Diseases</i> , <b>2014</b> , 73, A53.1-A53	2.4	1
56	Dr. Eisenberg replies. <i>Journal of Rheumatology</i> , <b>2013</b> , 40, 734	4.1	1
55	Concurrent oral 4 [Connective tissue diseaseOP22. B Cell Numbers and Phenotype at Clinical Relapse Following Rituximab Therapy Differ in SLE Patients According to Anti-Dsdna Antibody Titres. <i>Rheumatology</i> , <b>2011</b> , 50, iii40-iii42	3.9	1
54	mAbs in nonlupus autoimmune rheumatic disease. <i>Current Opinion in Hematology</i> , <b>2009</b> , 16, 280-4	3.3	1
53	The clinical relevance of antibodies to ribosomal Pwhere are we now?. <i>Japanese Journal of Rheumatology</i> , <b>1997</b> , 7, 235-245		1
52	Assessing lupus. <i>Arthritis and Rheumatism</i> , <b>1998</b> , 41, 2276-2276		1
51	Inflammatory muscle disease assessment. <i>Current Rheumatology Reports</i> , <b>2008</b> , 10, 328-32	4.9	1
50	Usefulness of the British Isles Lupus Assessment Group index in pediatric clinical trials: comment on the article by Ruperto et al. <i>Arthritis and Rheumatism</i> , <b>2006</b> , 54, 2343-4		1
49	Optimisation of herpes simplex virus-based vectors for delivery to human peripheral blood mononuclear cells. <i>Journal of Immunological Methods</i> , <b>2002</b> , 270, 235-46	2.5	1
48	Autoimmune rheumatic diseases and the heart. <i>British Journal of Hospital Medicine</i> , <b>1999</b> , 60, 95-9		1
47	Glycosylation of Immunoglobulins. <i>BioDrugs</i> , <b>1994</b> , 1, 169-172		1
46	Tropical rheumatology. Immunological aspects. <i>Baillierels Clinical Rheumatology</i> , <b>1995</b> , 9, 215-29		1

45	Multispecific monoclonal antibodies. <i>Trends in Immunology</i> , <b>1986</b> , 7, 354-5		1
44	Metabolomics in juvenile-onset SLE: identifying new biomarkers to predict cardiovascular risk		1
43	Disparity in Peripheral and Renal B-cell Depletion with Rituximab in Systemic Lupus Erythematosus: an Opportunity for Obinutuzumab?. <i>Rheumatology</i> , <b>2021</b> ,	3.9	1
42	Systemic Lupus Erythematosus: Direct B-Cell Blocking. <i>Milestones in Drug Therapy</i> , <b>2014</b> , 65-78		1
41	Idiotypes of DNA-Binding Autoantibodies: Mapping by Epitope Scanning and Molecular Modelling <b>1994</b> , 173-189		1
40	Inactive disease in lupus patients is linked to autoantibodies to type-I interferons that normalize blood IFN $\beta$ and B cell subsets		1
39	Prevalence and outcome of thrombocytopenia in systemic lupus erythematosus: single-centre cohort analysis. <i>Clinical and Experimental Rheumatology</i> , <b>2021</b> , 39, 601-605	2.2	1
38	Systemic phenotype related to primary Sjögren's syndrome in 279 patients carrying isolated anti-La/SSB antibodies. <i>Clinical and Experimental Rheumatology</i> , <b>2020</b> , 38 Suppl 126, 85-94	2.2	1
37	B-cell-targeted therapies: promising new treatments for systemic lupus erythematosus. <i>Future Rheumatology</i> , <b>2008</b> , 3, 59-68		0
36	Use of Glomerular CD68+ Cells as a Surrogate Marker for Endocapillary Hypercellularity in Lupus Nephritis.. <i>Kidney International Reports</i> , <b>2022</b> , 7, 841-847	4.1	0
35	Commentary: Systematic Review of Safety and Efficacy of Atacicept in Treating Immune-Mediated Disorders. <i>Frontiers in Immunology</i> , <b>2020</b> , 11, 592639	8.4	0
34	IgG vs IgG + IgM anti-double stranded DNA measurement: a comparative report for clinical practice. <i>Rheumatology</i> , <b>2021</b> , 60, 3951-3952	3.9	0
33	Antinuclear Antibodies, Antibodies to DNA, Histones, and Nucleosomes <b>2019</b> , 355-365		0
32	Total plaque area and plaque echogenicity are novel measures of subclinical atherosclerosis in patients with systemic lupus erythematosus. <i>Rheumatology</i> , <b>2021</b> , 60, 4185-4198	3.9	0
31	The origins, evolution and future of the International Myositis Assessment and Clinical Studies Group (IMACS). <i>Clinical and Experimental Rheumatology</i> , <b>2022</b> , 40, 214-218	2.2	0
30	Influence of the age at diagnosis in the disease expression of primary Sjögren syndrome. Analysis of 12,753 patients from the Sjögren Big Data Consortium. <i>Clinical and Experimental Rheumatology</i> , <b>2021</b> , 39, 166-174	2.2	0
29	Thrombocytopenia in the Antiphospholipid Syndrome. <i>Handbook of Systemic Autoimmune Diseases</i> , <b>2017</b> , 121-130	0.3	
28	Recognition and management of systemic lupus erythematosus. <i>The Prescriber</i> , <b>2019</b> , 30, 13-20	0.4	

27	Eric Bywaters a life story: 1 June 1910 to 2 April 2003. <i>Annals of the Rheumatic Diseases</i> , <b>2020</b> , 79, 996-998	2.4
26	Comment on: Musculoskeletal complication of haematological disease: Reply. <i>Rheumatology</i> , <b>2017</b> , 56, 321	3.9
25	Obituary for Paul Bacon. <i>Rheumatology</i> , <b>2018</b> , 57, 943-945	3.9
24	Recent advances in the treatment of systemic lupus erythematosus. <i>International Journal of Clinical Rheumatology</i> , <b>2014</b> , 9, 89-100	1.5
23	Systemic lupus erythematosus and the role of the GP. <i>The Prescriber</i> , <b>2015</b> , 26, 31-35	0.4
22	"Muscles and bones". <i>Arthritis and Rheumatism</i> , <b>2010</b> , 62, 2616-8	
21	The clinical relevance of antibodies to ribosomal P <sub>0</sub> where are we now?. <i>Japanese Journal of Rheumatology</i> , <b>1997</b> , 7, 235-245	
20	Use of phage expression to analyze regions of a human V4-34(VH4-21)-encoded IgG autoantibody required for recognition of DNA. No involvement of the 9G4 idiotope. <i>Annals of the New York Academy of Sciences</i> , <b>1997</b> , 815, 338-41	6.5
19	Autoimmune diseases. <i>Medicine</i> , <b>2008</b> , 36, 279-283	0.6
18	Introduction to a systemic lupus erythematosus - biomarkers meeting held at University College London on 23rd and 24th February 2007. <i>Lupus</i> , <b>2008</b> , 17, 231	2.6
17	Chapter 15 Systemic Lupus Erythematosus and Endocrine Disorders. <i>Handbook of Systemic Autoimmune Diseases</i> , <b>2008</b> , 9, 173-184	0.3
16	Therapeutic potential (1). <i>Lupus</i> , <b>2008</b> , 17, 259-61	2.6
15	Conversion of discoid lupus to antiphospholipid syndrome and SLE. <i>Nature Clinical Practice Rheumatology</i> , <b>2008</b> , 4, 106-10	
14	Relative Importance of Different Human aPL Derived Heavy and Light Chains in the Binding of aPL to Cardiolipin. <i>Clinical Science</i> , <b>2003</b> , 104, 47P-47P	
13	What's new in Autoimmune rheumatic diseases. <i>Medicine</i> , <b>2002</b> , 30, 1-4	0.6
12	Fine binding characteristics of human autoantibodies?partial molecular characterization. <i>Molecular Immunology</i> , <b>2004</b> , 41, 495-495	4.3
11	Inflammatory Muscle Diseases: Pathogenesis and Clinical Features. <i>Handbook of Systemic Autoimmune Diseases</i> , <b>2004</b> , 3, 107-128	0.3
10	Cyclophosphamide: Time to Say Goodnight and Goodbye?. <i>Current Rheumatology Reviews</i> , <b>2005</b> , 1, 189-196	1.6

- 9 Autoantibodies in Systemic Lupus Erythematosus **1999**, 156-162
- 8 Sequence features of monoclonal antiphospholipid antibodies: comment on the article by Ikematsu et al. *Arthritis and Rheumatism*, **1999**, 42, 1783-4
- 7 Autoimmunity in Systemic Lupus Erythematosus **2005**, 505-514
- 6 Immunopathogenesis of systemic lupus erythematosus. *Future Rheumatology*, **2007**, 2, 93-103
- 5 Myositis. *Contemporary Clinical Neuroscience*, **2019**, 787-808 0.1
- 4 Chronic Infection and Autoimmunity. *Medical Science Symposia Series*, **1994**, 61-66
- 3 Comment on: Lupus Low Disease Activity State (LLDAS) attainment discriminates responders in a systemic lupus erythematosus trial: post-hoc analysis of the Phase IIb MUSE trial of anifrolumab by Eric Morand. *Annals of the Rheumatic Diseases*, **2019**, 78, e121 2.4
- 2 CRESS: improving the assessment of disease activity in Sjögren's syndrome. *Lancet Rheumatology, The*, **2021**, 3, e534-e535 14.2
- 1 Influence of the age at diagnosis in the disease expression of primary Sjögren syndrome. Analysis of 12,753 patients from the Sjögren Big Data Consortium.. *Clinical and Experimental Rheumatology*, **2021**, 39 Suppl 133, 166-174 2.2